Digital health is undergoing a shift which is driven by advances in artificial intelligence and a repricing of software multiples. For much of the past decade, the sector has been built on SaaS models; recurring revenues, workflow tools, and expanding product offerings. SaaS models built around selling standalone software are under pressure in healthcare, where buyers expect solutions to show clear outcomes rather than just improve workflows.

AI is pushing companies beyond software sales and toward delivering measurable results. Across healthcare systems, AI is being integrated into clinical workflows, administration, and R&D. AI enabled clinical assistants are already reducing documentation time and supporting clinical decisions, while automation in areas such as claims and scheduling is lowering costs and improving efficiency, as highlighted by Boston Consulting Group. As these tools improve, the line between software and service delivery is becoming less clear.

At the same time, public market conditions have led investors to reassess SaaS valuations. As noted by Bain, higher interest rates and slower growth have reduced multiples, while AI focused businesses are raising questions about how defensible many software products are. Commentary from Uncover Alpha also suggests that standalone SaaS products are increasingly being incorporated into broader AI driven platforms.

In healthcare, the effects are already visible. Traditional SaaS businesses have typically been valued on retention, margins, and revenue growth. Increasingly, value is tied to control of data, clinical integration, and the ability to demonstrate outcomes. AI is enabling more predictive and personalised care, drawing on real world data, genomics, and patient generated inputs.

For investors, this changes how businesses are assessed. Revenue visibility remains important, but greater weight is being placed on proprietary data, regulatory positioning, and how embedded a product is within clinical workflows. Companies that become part of core healthcare processes are likely to achieve stronger valuations, while others may struggle as buyers focus on fewer, more integrated solutions.

#HealthTech #Valuations #CorporateFinance #Investment